Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pediatric cefiderocol safety, tolerability, and pharmacokinetics study in hospitalized patients with Gram-negative bacterial infections
2019-002120-32Phase 2Completed
- Sponsor
- Shionogi & Co., Ltd.
- Start
- Oct 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of cefiderocol in Gram-negative bacterial infection, complicated urinary tract infection (cUTI), Intra-abdominal infection (IAI) and 4 more, sponsored by Shionogi & Co., Ltd. Primary endpoint: Safety, tolerability and pharmacokinetics. Started Oct 2019; status: completed.
02
Drugs
cefiderocol
03
Conditions
Gram-negative bacterial infectioncomplicated urinary tract infection (cUTI)Intra-abdominal infection (IAI)hospital-acquired pneumonia (HAP)ventilator-associated pneumonia (VAP)
Beyond the preview
Go deeper on 2019-002120-32.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2019-002120-32.